AUTHORS
Neha Mehta-Shah, MD, MSCI, Amy Musiek, MD2, Erika Crawford3, Chaz Moreno4, Nicole C. Foley, MD5, Amanda Cashen, MD6, Nancy L. Bartlett, MD7, Brad S. Kahl, MD8, Joanna Yang, MD, MPH9, Phoenix Hollenbeck10, Fei Wan, PhD11, George Souroullas, PhD12, Jacqueline E. Payton, MD, PhD13
AFFILIATIONS
1 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
2 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
3 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
4 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
5 University of California-Irvine, Irvine, California, United States
6 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
7 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
8 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
9 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
10 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
11 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
12 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
13 Washington University in St. Louis School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Background:
Pts with advanced stage cutaneous T-cell lymphomas (CTCL) have poor prognosis and limited treatment options. Most approved therapies have overall response rates (ORR) of 20-40% and median duration of response (DOR) 4-12 mo and carry cumulative toxicity with burdensome schedules. EZH2 inhibitors (EZH2i) have shown efficacy in other T-cell lymphomas but have not been studied in CTCL. We recently published that copy number amplification and over-expression of EZH2 are frequent in progressive advanced-stage CTCL. (Dorando Blood 2026) Therefore, we conducted an investigator-initiated study of tulmimetostat, an oral dual EZH1/2i, in patients (pts) with CTCL at Washington University in St. Louis.
Methods:
Eligible pts had pathologically confirmed stage ≥IB CTCL with measurable disease by the Global Response Criteria for CTCL and ≥1 prior systemic therapy. The primary objective was to determine safety and tolerability of tulmimetostat in CTCL. The secondary objectives were to establish the recommended phase II dose (RP2D) and evaluate preliminary efficacy, as measured by ORR, ORR at 4 mo (ORR4), complete remission (CR) rate, and DOR. Exploratory endpoints were to evaluate quality of life (QOL) and biomarkers predictive of therapy response/resistance. QOL by SkinDex-29 was measured at baseline and every 3 mo.
Oral tulmimetostat was given daily until progression or intolerance (cycle 28 days). The phase I study was conducted in a 3+3 dose de-escalation design with a starting dose of 300mg daily and a 12-patient expansion. An additional cohort (n=6) starting at 200mg daily was later added due to observed cumulative toxicities. Dose-limiting toxicities (DLTs) were assessed in cycle 1. Treatment was deemed tolerable if <2/6 DLTs were observed. DLTs were defined as: ≥grade 3 non-hematologic toxicities; ≥grade 4 hematologic toxicities; neutropenic fever; or thrombocytopenia with significant bleeding.
Results
24 pts were enrolled from 1/2024-2/2026 with a median age of 71 years (range 31-86), 5 female, 19 white and 5 black. 19 had mycosis fungoides and 5 had Sezary syndrome with stages: IB (n=7), IIA (n=5), IIB (n=5), IIIA (n=1), IIIB (n=1), IVA (n=5). Median number of prior therapies was 3 (range 1-11).
There were no DLTs in the dose finding portion and tulmimetostat 300mg daily was determined to be the RP2D.
Treatment related adverse events (TRAE) of any grade in the whole cohort included diarrhea (79%), dysgeusia (75%), nausea (38%), fatigue (29%), anorexia (21%), thrombocytopenia (21%), anemia (17%), constipation (13%), skin infections (13%), peripheral neuropathy (13%) and maculo-papular rash (13%). Grade 3-4 TRAE occurred in 14 (58%) pts including grade 3 diarrhea (13%), skin infections (13%), colitis (8%), thrombocytopenia (8%), nausea (8%), urinary tract infection (4%), wound infection (4%), erythroderma (4%) and anorexia (4%) and no grade 5 TRAE. All pts on therapy >2 cycles required dose reduction at a median of 4 cycles (range 1-12).
For the whole cohort, best ORR was 62.5% (2 CR, 13 PR). ORR4 was 41.7% (10 PR). For pts who started at 300mg and 200mg respectively, best ORR was 72.2% (13/18) and 33% (2/6). The median DOR was 17.9 mo (95% CI, 1.8 mo to not estimable). Pts who discontinued therapy (n=14) were due to progression (n=12), erythroderma (n=1), and consolidative allogenic transplant (n=1). 10 pts remain on treatment.
At a median follow up of 11.4 mo, the median progression-free survival (PFS) was 11.5 mo (95% CI: 3.7 mo to not estimable) and median OS was not reached. The estimated PFS rates were 56.7% (95% CI: 34.3%–74.0%) at 6 mo, and 45.5% (95% CI: 23.6%–65.0%) at 12 mo. Kaplan-Meier estimated OS rates were 94.4% (95% CI: 66.6%–99.2%) at 6 mo, and 67.4% (95% CI: 38.0%–85.2%) at 12 mo.
Regarding QOL, among pts with paired baseline and on-treatment data, median pretreatment Skindex-29 (n=15) was 26.7 (range, 8.6–93.1), with a median on-treatment nadir of 16.4 (0–40.5). After 4 cycles, SkinDex29 improved by a mean of 16.5 points (n=10; p=0.031). Correlating to best response, median SkinDex29 improvement was 16.4 points in pts with CR/PR (n=11) and 19.4 points in those with SD (n=4).
Conclusion:
Tulmimetostat, an oral EZH2i, demonstrates an ORR 62.5% with median DOR 17.9 mo and significant improvement in QOL by SkinDex29 in heavily pretreated pts with R/R CTCL. Pts remained on therapy but required dose reductions for cumulative toxicity. Results of multi-omic studies will be discussed at the time of presentation.
DISCLOSURES
Neha Mehta-Shah, MD, MSCI: MDEducation - Honoraria; MedLive - Honoraria; Curio Science - Honoraria; BioAscend - Honoraria; C4 Pharmaceuticals - Research Funding; Seagen/Pfizer - Research Funding; Ono Pharmaceuticals - Research Funding; Daiichi Sankyo - Research Funding; Treeline Pharmaceuticals - Research Funding; AstraZeneca - Research Funding; Morphosys/Novartis - Research Funding; Novartis - Research Funding; Innate Pharmaceuticals - Research Funding; BMS/Celgene - Research Funding; Corvus Pharmaceuticals - Research Funding; Genenetch - Research Funding; Pfizer - Research Funding; SecuraBio - Research Funding; Autolous - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); SecuraBio - Consultancy (Includes expert testimony); Ono Pharmaceuticals - Consultancy (Includes expert testimony); Acrotech - Consultancy (Includes expert testimony)